Next Article in Journal
The Herb–Drug Pharmacokinetic Interaction of 5-Fluorouracil and Its Metabolite 5-Fluoro-5,6-Dihydrouracil with a Traditional Chinese Medicine in Rats
Next Article in Special Issue
Metabolic Features of Multiple Myeloma
Previous Article in Journal
BMP Signalling at the Crossroad of Liver Fibrosis and Regeneration
Article Menu
Issue 1 (January) cover image

Export Article

Open AccessBrief Report
Int. J. Mol. Sci. 2018, 19(1), 40;

Decitabine and Melphalan Fail to Reactivate p73 in p53 Deficient Myeloma Cells

CRCINA, INSERM, CNRS, Université d’Angers, Université de Nantes, 44007 Nantes, France
Service d’Hématologie Clinique, Unité d’Investigation Clinique, CHU, 44093 Nantes, France
Author to whom correspondence should be addressed.
Received: 25 November 2017 / Revised: 20 December 2017 / Accepted: 22 December 2017 / Published: 23 December 2017
(This article belongs to the Special Issue Novel Therapeutic Strategies in Multiple Myeloma)
Full-Text   |   PDF [1296 KB, uploaded 23 December 2017]   |  


(1) Background: TP53 deficiency remains a major adverse event in Multiple Myeloma (MM) despite therapeutic progresses. As it is not possible to target TP53 deficiency with pharmacological agents, we explored the possibility of activating another p53 family member, p73, which has not been well studied in myeloma. (2) Methods: Using human myeloma cell lines (HMCLs) with normal or abnormal TP53 status, we assessed TP73 methylation and expression. (3) Results: Using microarray data, we reported that TP73 is weakly expressed in 47 HMCLs and mostly in TP53 wild type (TP53wt) HMCLs (p = 0.0029). Q-RT-PCR assays showed that TP73 was expressed in 57% of TP53wt HMCLs (4 out of 7) and 11% of TP53 abnormal (TP53abn) HMCLs (2 out of 18) (p = 0.0463). We showed that TP73 is silenced by methylation in TP53abn HMCLs and that decitabine increased its expression, which, however, remained insufficient for significant protein expression. Alkylating drugs increased expression of TP73 only in TP53wt HMCLs but failed to synergize with decitabine in TP53abn HMCLs. (4) Conclusions: Decitabine and melphalan does not appear as a promising combination for inducing p73 and bypassing p53 deficiency in myeloma cells. View Full-Text
Keywords: multiple myeloma; p53; p73; CpG methylation; decitabine; alkylating drugs multiple myeloma; p53; p73; CpG methylation; decitabine; alkylating drugs

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Gillardin, P.-S.; Descamps, G.; Maiga, S.; Tessoulin, B.; Djamai, H.; Lucani, B.; Chiron, D.; Moreau, P.; Le Gouill, S.; Amiot, M.; Pellat-Deceunynck, C.; Moreau-Aubry, A. Decitabine and Melphalan Fail to Reactivate p73 in p53 Deficient Myeloma Cells. Int. J. Mol. Sci. 2018, 19, 40.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top